- Coloplast reported second-quarter revenue of DKK6.93 billion, falling short of the estimated DKK7.01 billion.
- Sales in Emerging Markets outperformed expectations at DKK1.19 billion compared to the estimate of DKK1.11 billion.
- European revenue came in at DKK3.81 billion, missing the projected DKK3.93 billion.
- Other developed markets also saw revenue below expectations, with DKK1.93 billion versus the anticipated DKK1.99 billion.
- EBITDA slightly exceeded analyst predictions, registering DKK2.24 billion against an estimated DKK2.23 billion.
- Earnings Before Interest and Taxes (EBIT) stood at DKK1.81 billion.
- Net income amounted to DKK912 million, underperforming the estimated DKK1.01 billion.
- Analyst recommendations included 11 buys, 15 holds, and 2 sells.
A look at Coloplast A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coloplast A/S, a company that develops healthcare products, has a mixed outlook according to Smartkarma Smart Scores. With a Value score of 2, the company may not be considered undervalued in the market. However, its Dividend score of 4 indicates strong potential for dividend payments, making it an attractive option for income investors. In terms of Growth, Coloplast scores a 3, suggesting moderate growth prospects in the long term. The company also shows resilience with a score of 3, indicating its ability to weather economic uncertainties. Additionally, with a Momentum score of 3, Coloplast is displaying consistent performance trends.
Overall, Coloplast A/S seems to be a company with stable fundamentals and a promising dividend payout. While it may not be seen as significantly undervalued, its consistent growth and resilience make it an interesting consideration for investors looking for steady returns. With its wide range of healthcare products and global presence, Coloplast is well-positioned to capitalize on the growing demand for its offerings in the healthcare market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
